Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03093844 · ClinicalTrials.gov registry record · NA
Haploidentical CD34+ Selected Cells Combined With Single Unit Umbilical Cord Blood Transplant for Treatment of High-risk Hematologic Disorders
A NA study of Hematologic Disorders, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT03093844 is a NA study of Hematologic Disorders that has completed, run by University of Colorado, Denver. The registered enrollment target is 150 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03093844, a NA study of Hematologic Disorders, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to evaluate the safety and efficacy of Miltenyi CliniMACS® CD34 Reagent System to promote engraftment of haploidentical CD34+ selected cells combined with single unit umbilical cord blood transplant for treatment of high-risk hematologic disorders.
Conditions Studied
Interventions
- DEVICE Miltenyi CliniMACS® CD34 Reagent System
Study Locations (1)
Colorado
- University of Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2017-10-12 |
| Est. Completion | 2025-02-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03093844
The ClinicalTrials.gov registry entry for NCT03093844 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Disorders appearing as the primary indexed condition, and to 1 intervention - of which Miltenyi CliniMACS® CD34 Reagent System is the first listed.
NCT03093844 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT03093844 about?
NCT03093844 is a clinical study titled "Haploidentical CD34+ Selected Cells Combined With Single Unit Umbilical Cord Blood Transplant for Treatment of High-risk Hematologic Disorders". This is a study to evaluate the safety and efficacy of Miltenyi CliniMACS® CD34 Reagent System to promote engraftment of haploidentical CD34+ selected cells combined with single unit umbilical cord blood transplant for treatment of high-risk hematologic disorders.
What is the current status of trial NCT03093844?
This trial is currently completed. It is a NA study. The enrollment target is 150 participants. The study started on 2017-10-12. Estimated completion is 2025-02-05.
What conditions does trial NCT03093844 study?
This clinical trial studies the following conditions: Hematologic Disorders.
What interventions are being tested in trial NCT03093844?
The interventions under investigation include: Miltenyi CliniMACS® CD34 Reagent System (DEVICE).
Who is sponsoring clinical trial NCT03093844?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03093844 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.